Literature DB >> 22794786

Gene therapy approaches for lysosomal storage disease: next-generation treatment.

Barry J Byrne1, Darin J Falk, Nathalie Clément, Cathryn S Mah.   

Abstract

Lysosomal storage diseases are a group of rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. These diseases are characterized by progressive accumulation of storage material within the lysosomes of affected cells, ultimately leading to cellular dysfunction. Multiple tissues ranging from musculoskeletal and visceral to tissues of the central nervous system are typically involved in disease pathology. Since the advent of enzyme replacement therapy (ERT) to manage some LSDs, general clinical outcomes have significantly improved; however, treatment with infused protein is lifelong and continued disease progression is still evident in patients. Viral gene therapy may provide a viable alternative or adjunctive therapy to current management strategies for LSDs. In this review, we discuss the various viral vector systems that have been developed and some of the strategy designs for the treatment of LSDs.

Entities:  

Mesh:

Year:  2012        PMID: 22794786      PMCID: PMC3413894          DOI: 10.1089/hum.2012.140

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  70 in total

1.  Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII.

Authors:  Y Kamata; A Tanabe; A Kanaji; M Kosuga; Y Fukuhara; X-K Li; S Suzuki; M Yamada; N Azuma; T Okuyama
Journal:  Gene Ther       Date:  2003-03       Impact factor: 5.250

Review 2.  Virus-based gene delivery systems.

Authors:  Cathryn Mah; Barry J Byrne; Terence R Flotte
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.

Authors:  Mary Rucker; Thomas J Fraites; Stacy L Porvasnik; Melissa A Lewis; Irene Zolotukhin; Denise A Cloutier; Barry J Byrne
Journal:  Development       Date:  2004-06       Impact factor: 6.868

Review 4.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

Review 5.  Strategies to modulate immune responses: a new frontier for gene therapy.

Authors:  Valder R Arruda; Patricia Favaro; Jonathan D Finn
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

6.  Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.

Authors:  Cathryn Mah; Christina A Pacak; Kerry O Cresawn; Lara R Deruisseau; Sean Germain; Melissa A Lewis; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2007-01-23       Impact factor: 11.454

7.  Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.

Authors:  Mai K ElMallah; Darin J Falk; Michael A Lane; Thomas J Conlon; Kun-Ze Lee; Nadeem I Shafi; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Hum Gene Ther Methods       Date:  2012-04       Impact factor: 2.396

Review 8.  Treatment of lysosomal storage disorders: cell therapy and gene therapy.

Authors:  Y Eto; J-S Shen; X-L Meng; T Ohashi
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 9.  Immunology of neonatal gene transfer.

Authors:  Katherine P Ponder
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

10.  Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.

Authors:  Mario A Cabrera-Salazar; Eric M Roskelley; Jie Bu; Bradley L Hodges; Nelson Yew; James C Dodge; Lamya S Shihabuddin; Istvan Sohar; David E Sleat; Ronald K Scheule; Beverly L Davidson; Seng H Cheng; Peter Lobel; Marco A Passini
Journal:  Mol Ther       Date:  2007-07-17       Impact factor: 11.454

View more
  22 in total

Review 1.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

2.  Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.

Authors:  Haiyan Fu; Aaron S Meadows; Tierra Ware; Robert P Mohney; Douglas M McCarty
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

Review 3.  Targeting long non-coding RNA to therapeutically upregulate gene expression.

Authors:  Claes Wahlestedt
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

4.  Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain.

Authors:  W Lerchner; B Corgiat; V Der Minassian; R C Saunders; B J Richmond
Journal:  Gene Ther       Date:  2014-01-09       Impact factor: 5.250

5.  Can manipulation of splicing offer gene therapy possibilities to those with tumour-prone disorders?

Authors:  D Gareth R Evans; Andrew Wallace; William Newman
Journal:  Eur J Hum Genet       Date:  2012-11-28       Impact factor: 4.246

Review 6.  Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.

Authors:  Adeline A Lau; Kim M Hemsley
Journal:  J Mol Med (Berl)       Date:  2017-06-29       Impact factor: 4.599

7.  Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy.

Authors:  Martin K Childers; Romain Joubert; Karine Poulard; Christelle Moal; Robert W Grange; Jonathan A Doering; Michael W Lawlor; Branden E Rider; Thibaud Jamet; Nathalie Danièle; Samia Martin; Christel Rivière; Thomas Soker; Caroline Hammer; Laetitia Van Wittenberghe; Mandy Lockard; Xuan Guan; Melissa Goddard; Erin Mitchell; Jane Barber; J Koudy Williams; David L Mack; Mark E Furth; Alban Vignaud; Carole Masurier; Fulvio Mavilio; Philippe Moullier; Alan H Beggs; Anna Buj-Bello
Journal:  Sci Transl Med       Date:  2014-01-22       Impact factor: 17.956

8.  Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.

Authors:  F Jason Duncan; Bartholomew J Naughton; Kimberly Zaraspe; Darren A Murrey; Aaron S Meadows; Kelly Reed Clark; David E Newsom; Peter White; Haiyan Fu; Douglas M McCarty
Journal:  Mol Ther       Date:  2015-01-16       Impact factor: 11.454

9.  Transcriptome assessment of the Pompe (Gaa-/-) mouse spinal cord indicates widespread neuropathology.

Authors:  S M F Turner; D J Falk; B J Byrne; D D Fuller
Journal:  Physiol Genomics       Date:  2016-09-09       Impact factor: 3.107

10.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.